GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Other Net Income (Loss)

Mankind Pharma (BOM:543904) Other Net Income (Loss) : ₹0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Other Net Income (Loss)?

Mankind Pharma's Other Net Income (Loss) for the three months ended in Mar. 2024 was ₹0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0 Mil.

Mankind Pharma's annual Other Net Income (Loss) increased from Mar. 2022 (₹-0 Mil) to Mar. 2023 (₹0 Mil) and increased from Mar. 2023 (₹0 Mil) to Mar. 2024 (₹0 Mil).


Mankind Pharma Other Net Income (Loss) Historical Data

The historical data trend for Mankind Pharma's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Other Net Income (Loss) Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Other Net Income (Loss)
- - - - -

Mankind Pharma Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mankind Pharma Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mankind Pharma Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mankind Pharma (BOM:543904) Business Description

Traded in Other Exchanges
Address
262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines